Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Cancer Research|December 5, 2015
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In VivoStefan Lohse, Saskia Meyer, Laura A P M Meulenbroek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineageTanja Schneider-Merck, Jeroen J Lammerts van Bueren, Sven Berger, et al.
Cancer Immunology Research|September 27, 2015
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell KillingArianne M Brandsma, Toine Ten Broeke, Maaike Nederend, et al.
The Journal of Clinical Investigation|February 9, 2021
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicityNiels Heemskerk, Mandy Gruijs, A Robin Temming, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Bone Marrow Transplantation|May 2, 2022
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Cancer Immunology Research|November 7, 2019
IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint InhibitionLouise W Treffers, Toine Ten Broeke, Thies Rösner, et al.
EMBO Molecular Medicine|August 7, 2013
IgA EGFR antibodies mediate tumour killing in vivoPeter Boross, Stefan Lohse, Maaike Nederend, et al.
Frontiers in Immunology|November 17, 2022
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophagesTobias Zeller, Sebastian Lutz, Ira A Münnich, et al.
Blood|April 22, 2022
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALLKristina Müller, Fotini Vogiatzi, Dorothee Winterberg, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Cancer Research|December 5, 2015
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In VivoStefan Lohse, Saskia Meyer, Laura A P M Meulenbroek, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2009
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineageTanja Schneider-Merck, Jeroen J Lammerts van Bueren, Sven Berger, et al.
Cancer Immunology Research|September 27, 2015
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell KillingArianne M Brandsma, Toine Ten Broeke, Maaike Nederend, et al.
The Journal of Clinical Investigation|February 9, 2021
Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicityNiels Heemskerk, Mandy Gruijs, A Robin Temming, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Bone Marrow Transplantation|May 2, 2022
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Cancer Immunology Research|November 7, 2019
IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint InhibitionLouise W Treffers, Toine Ten Broeke, Thies Rösner, et al.
EMBO Molecular Medicine|August 7, 2013
IgA EGFR antibodies mediate tumour killing in vivoPeter Boross, Stefan Lohse, Maaike Nederend, et al.
Frontiers in Immunology|November 17, 2022
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophagesTobias Zeller, Sebastian Lutz, Ira A Münnich, et al.
Blood|April 22, 2022
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALLKristina Müller, Fotini Vogiatzi, Dorothee Winterberg, et al.
Pageof 11